N-(diethylamino)carbonyl-L-phenylalanine | 63524-76-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(diethylamino)carbonyl-L-phenylalanine
• 英文别名: N-diethylcarbamoyl-L-phenylalanine；N-(Diethylcarbamoyl)-L-phenylalanine；(2S)-2-(diethylcarbamoylamino)-3-phenylpropanoic acid
• CAS: 63524-76-5
• 化学式: C₁₄H₂₀N₂O₃
• 分子量: 264.324
• InChiKey: LBFOOEJBTGNJDX-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(diethylamino)carbonyl-L-phenylalanine benzyl ester 生成 N-(diethylamino)carbonyl-L-phenylalanine
  参考文献：
  名称：

  Renin inhibitor peptide compounds, a process for the preparation thereof

  摘要：

  该化合物的结构式为：##STR1##其中R.sup.1为芳基，可选择地取代为卤素和卤代(低)烷基；低烷基或环(低)烷基；R.sup.2为氢或低烷基，或R.sup.1和R.sup.2与连接的氮原子一起形成一个杂环基，可选择地取代为低烷基和酯化羧基；R.sup.3为氢或低烷基，R.sup.4为低烷基，以及其药学上可接受的盐，制备方法和包含该化合物的药物组合物。

  公开号：

  US04963530A1

文献信息

• New peptide compounds, a process for the preparation thereof and pharmaceutical composition comprising the same
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP0283970A2

  公开（公告）日：1988-09-28

  A compound of the formula : wherein R1 is aryl optionally substituted with a substituent selected from the group consisting of halogen and halo(lower)alkyl; lower alkyl or cyclo(lower)alkyl; and R2 is hydrogen or lower alkyl, or R' and R2 are taken together with the attached nitrogen atom to form a heterocylic group optionally substituted with a substituent selected from the group consisting of lower alkyl and esterified carboxy, R3 is hydrogen or lower alkyl, and R4 is lower alkyl, and its pharmaceutically acceptable salt, a process for the preparation thereof and pharmaceutical composition comprising the same

  式中的化合物： 其中 R1 是芳基，可任选被选自由卤素和卤代（低级）烷基组成的取代基取代； 低级烷基或环（低级）烷基；以及 R2 是氢或低级烷基，或 R' 和 R2 与相连的氮原子一起形成杂环基团，该杂环基团可选择被选自低 级烷基和酯化羧基的取代基取代、 R3 是氢或低级烷基，以及 R4 是低级烷基、 及其药学上可接受的盐、其制备方法和包含其的药物组合物
• DIOXACYCLOALKANE COMPOUND WITH RENIN-INHIBITING ACTIVITY
  申请人：JAPAN TOBACCO INC.

  公开号：EP0656356A1

  公开（公告）日：1995-06-07

  A dioxacycloalkane compound represented by general formula [1], a pharmaceutically acceptable salt thereof, an intermediate for producing the compound, and a process for producing the intermediate. The compound [1] has a potent activity of inhibiting renin and a persistent hypotensive effect by peroral administration, thus being useful as a hypotensive and a remedy for cardiac insufficiency. General formula [1] wherein A represents [a] or [b]; W represents [c], [d] or [e], X represents -CO- or -SO₂-; Y represents -CH₂, -O- or -NR²⁵-; R¹ represents aralkyl which may be substituted by lower alkoxy; R² represents hydrogen or lower alkyl; R³ represents -(CH₂)d-SR²⁶ or [f]; R⁴ and R⁵ represent each hydrogen or lower alkyl; and E represents -C(R²⁹)(R³⁰)- or -CH₂CH₂-.

  一种由通式[1]表示的二氧环烷烃化合物、其药学上可接受的盐、生产该化合物的中间体以及生产该中间体的工艺。该化合物[1]具有抑制肾素的强效活性，口服给药具有持续降压作用，因此可用作降压药和治疗心功能不全的药物。通式[1] 其中 A 代表[a]或[b]；W 代表[c]、[d]或[e]，X 代表-CO-或-SO₂-；Y 代表-CH₂、-O-或-NR²⁵-；R¹ 代表可被低级烷氧基取代的芳烷基；R² 代表氢或低级烷基；R³ 代表-(CH₂)d-SR²⁶ 或 [f]；R⁴ 和 R⁵ 各自代表氢或低级烷基；以及 E 代表-C(R²⁹)(R³⁰)- 或 -CH₂CH₂-。
• US4963530A
  申请人：——

  公开号：US4963530A

  公开（公告）日：1990-10-16
• US5750696A
  申请人：——

  公开号：US5750696A

  公开（公告）日：1998-05-12
• Renin inhibitor peptide compounds, a process for the preparation thereof
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04963530A1

  公开（公告）日：1990-10-16

  A compound of the formula: ##STR1## wherein R.sup.1 is aryl optionally substituted with a substituent selected from the group consisting of halogen and halo(lower)alkyl; lower alkyl or cyclo(lower)alkyl; and R.sup.2 is hydrogen or lower alkyl, or R.sup.1 and R.sup.2 are taken together with the attached nitrogen atom to form a heterocyclic group optionally substituted with a substituent selected from the group consisting of lower alkyl and esterified carboxy, R.sup.3 is hydrogen or lower alkyl, and R.sup.4 is lower alkyl, and its pharmaceutically acceptable salt, a process for the preparation thereof and pharmaceutical composition comprising the same.

  该化合物的结构式为：##STR1##其中R.sup.1为芳基，可选择地取代为卤素和卤代(低)烷基；低烷基或环(低)烷基；R.sup.2为氢或低烷基，或R.sup.1和R.sup.2与连接的氮原子一起形成一个杂环基，可选择地取代为低烷基和酯化羧基；R.sup.3为氢或低烷基，R.sup.4为低烷基，以及其药学上可接受的盐，制备方法和包含该化合物的药物组合物。